Literature DB >> 32659155

Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia.

Pamela Hair1, Daniel W Goldman2, Jessica Li2, Michelle Petri2, Neel Krishna3, Kenji Cunnion1.   

Abstract

INTRODUCTION: Autoimmune hemolytic anemia (AIHA) is a serious manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. In order to more fully understand the causative pathways, we utilized sera from subjects with SLE and active AIHA, or a history of AIHA, to evaluate the classical complement pathway, anti-erythrocyte antibodies, and immune complexes.
METHODS: To evaluate antibody-mediated complement activation on the surface of erythrocytes, as occurs in AIHA, blood type O erythrocytes were incubated with sera from 19 subjects with SLE and a history of AIHA. Circulating anti-erythrocyte antibodies and immune complexes were measured with ELISA-based assays.
RESULTS: In total, 90% of subjects with SLE and a history of AIHA, but not active clinical hemolysis, had measurable anti-erythrocyte antibodies. Of those with anti-erythrocyte antibody, 53% demonstrated complement opsonization on the erythrocyte surface >twofold above negative control and 29% generated the anaphylatoxin C5a.
CONCLUSIONS: For subjects with SLE and a history of AIHA, the persistence of circulating anti-erythrocyte antibodies and resultant erythrocyte complement opsonization and anaphylatoxin generation suggests the possibility that these complement effectors contribute to chronic morbidity and risk of AIHA relapse.

Entities:  

Keywords:  Autoimmune hemolytic anemia (AIHA); peptide inhibitor of complement C1 (PIC1); systemic lupus erythematosus (SLE)

Mesh:

Substances:

Year:  2020        PMID: 32659155      PMCID: PMC8260106          DOI: 10.1177/0961203320936347

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  33 in total

Review 1.  Autoimmune hemolytic anemia.

Authors:  Anita Hill; Quentin A Hill
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Authors:  Quentin A Hill; Anita Hill; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-06-25

Review 3.  Cold agglutinin-mediated autoimmune hemolytic anemia.

Authors:  Sigbjørn Berentsen; Ulla Randen; Geir E Tjønnfjord
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-12       Impact factor: 3.722

Review 4.  Mechanisms of Complement-Mediated Damage in Hematological Disorders.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

Review 5.  Pathobiology of transfusion reactions.

Authors:  James C Zimring; Steven L Spitalnik
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

6.  Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Authors:  Wilma Barcellini; Bruno Fattizzo; Anna Zaninoni; Tommaso Radice; Ilaria Nichele; Eros Di Bona; Monia Lunghi; Cristina Tassinari; Fiorella Alfinito; Antonella Ferrari; Anna Paola Leporace; Pasquale Niscola; Monica Carpenedo; Carla Boschetti; Nicoletta Revelli; Maria Antonietta Villa; Dario Consonni; Laura Scaramucci; Paolo De Fabritiis; Giuseppe Tagariello; Gianluca Gaidano; Francesco Rodeghiero; Agostino Cortelezzi; Alberto Zanella
Journal:  Blood       Date:  2014-09-16       Impact factor: 22.113

Review 7.  Free heme toxicity and its detoxification systems in human.

Authors:  Sanjay Kumar; Uday Bandyopadhyay
Journal:  Toxicol Lett       Date:  2005-04-07       Impact factor: 4.372

8.  Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus.

Authors:  Pamela S Hair; Charlene G Echague; Reuben D Rohn; Neel K Krishna; Julius O Nyalwidhe; Kenji M Cunnion
Journal:  J Transl Med       Date:  2012-03-05       Impact factor: 5.531

9.  Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin.

Authors:  Pamela S Hair; Kenji M Cunnion; Neel K Krishna
Journal:  Int J Pept       Date:  2017-09-10

10.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

View more
  3 in total

1.  Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE.

Authors:  Simone Caielli; Jacob Cardenas; Adriana Almeida de Jesus; Jeanine Baisch; Lynnette Walters; Jean Philippe Blanck; Preetha Balasubramanian; Cristy Stagnar; Marina Ohouo; Seunghee Hong; Lorien Nassi; Katie Stewart; Julie Fuller; Jinghua Gu; Jacques F Banchereau; Tracey Wright; Raphaela Goldbach-Mansky; Virginia Pascual
Journal:  Cell       Date:  2021-08-11       Impact factor: 66.850

Review 2.  The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy.

Authors:  Neel K Krishna; Kenji M Cunnion; Grace A Parker
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

3.  Efficacy of Whole-Blood Exchange Transfusion in Refractory Severe Autoimmune Haemolytic Anaemia Secondary to Systemic Lupus Erythematosus: A Real-World Observational Retrospective Study.

Authors:  Ying Jiang; Hong Jun Zhao; Hui Luo; Bi Juan Li; Zhi Min Zhang; Li Dan Zhao; Xiao Xia Zuo
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.